RFK Jr.'s peptide policy could boost Hims & Hers as it pivots its GLP-1 business
Piotr Swat | Light rocket | fake images As its high-margin compounded LPG-1 business evolves, Health for him and her…
Hims & Hers Health Inc.
Eli Lilly GLP-1 Foundayo pill approved for obesity
The US Food and Drug Administration has approved Eli LillyThe GLP-1 pill, the company said, is a major milestone for…
Novo Nordisk launches Wegovy subscription for GLP-1 anti-obesity drugs
Wegovy semaglutide tablets. Michael Siluk | Universal Image Group | fake images Nordisk on Tuesday launched a multi-month subscription program…
Novo Nordisk ends legal proceedings against Hims & Hers
Nordisk has dropped its legal case against telehealth provider him and her for patent infringement, after the two companies agreed…
Eli Lilly Launches Program to Increase Employer Coverage of Obesity Drugs
Eli Lilly On Thursday it launched a new program designed to help more employers cover obesity medications in the U.S.,…
Why Novo Nordisk's expansion in Ireland is key to fighting Eli Lilly
Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capabilities to…
Eli Lilly launches anti-obesity drug Zepbound with one-month dosage
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York on March 28, 2024.…
Novo Nordisk Shares Fall as Weight Loss Drug Fails to Beat Eli Lilly
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, November 5, 2025. Nichlas Pollier | Bloomberg | fake images…
FDA Chief Marty Makary on GLP-1 Copies, Vaccines and China
U.S. Food and Drug Administration (FDA) Commissioner Marty Makary presents a study from The Lancet during an announcement of the…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Nordisk on Monday said he is suing an online telehealth provider him and her to mass market cheaper, unapproved copies…